Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2018

View Archived Issues

Mitsubishi Tanabe presents milestones of fourth quarter of fiscal 2017

First patient dosed in phase II study of eFT-508 plus avelumab in colorectal cancer

RXi Pharmaceuticals enters research agreement with Iovance Biotherapeutics

Porcine optic nerve injury model created to study nerve regeneration

Novel p95HER2-TCB demonstrates efficacy and safety in preclinical models of breast cancer

Merck & Co. patents KDM5B inhibitors

Shanghai Pharmaceuticals Holding discloses IDO-1 inhibitors

Bayer and collaborators identify DHOdehase inhibitors

BioIncept's PIF-1 designated as orphan drug by FDA for prevention of graft-versus-host-disease

FDA awards ImmunoGen's IMGN-779 orphan drug designation for AML

FDA approves Gilenya to treat MS in pediatric patients

Ono Pharmaceutical reflects on achievements of fourth quarter of fiscal 2017

Sanofi announces success of initial tender offer for acquisition of Ablynx

Inovio studies VGX-3100 in new phase II trial for HPV-16 or -18 related anal or peri-anal HSIL

Phase II trial in China studies SHR-1210 for advanced biliary tract cancer

Tumor growth inhibition seen with Jubilant Biosys LSD1/HDAC inhibitors

Medigene and bluebird bio expand TCR alliance

Human evaluation of CAR T cells targeting ROR1 underway

Beam Therapeutics launches with focus on creating precision genetic medicines through base editing

Poseida Therapeutics presents clinical data on P-BCMA-101 for relapsed/refractory multiple myeloma

Polaris collaborates with MD Anderson Cancer Center to utilize immunotherapy platform

CS-1003 begins phase I trial in advanced solid tumors